39 results
Beta-Blockers in Cirrhosis
 • Pathophysiology
 • Indications:  Prevention of decompensation, Prevention of first variceal bleeding,
Indications: Prevention ... decompensation, Prevention ... variceal bleeding, Prevention ... BetaBlockers #Cirrhosis #hepatology ... #management #pharmacology
Direct-acting oral anticoagulants (DOACs) for VTE treatment and prevention - Comparison Table

#DOAC #Anticoagulants #Anticoagulation #VTE #Management
DOACs) for VTE treatment ... and prevention ... - Comparison Table ... VTE #Management #Pharmacology ... #Comparison #Table
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
DAAs #Antivirals #table ... #treatment #hcv ... infectiousdisease #hepatology ... HepatitisC #Management #Pharmacology
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Rivaroxaban #Edoxaban #Loading ... #DVT #Pharmacology ... #Hematology
Conversion - Epoetin alfa (Procrit®) to Darbepoetin alfa (Aranesp™)

#Epoetin #Darbepoetin #Erythropoietin #Conversion #Table #ESAs #Procrit #Aranesp
Erythropoietin #Conversion #Table ... Procrit #Aranesp #Pharmacology ... #Hematology #Nephrology
Topical drug formulations, comparison and considerations

#pharmacology #table #medications #comparison #drugs #treatment #pharmacotherapy #dermatology
considerations #pharmacology ... #table #medications ... comparison #drugs #treatment ... pharmacotherapy #dermatology
Preventing Decompensation in Cirrhosis 

cACLD, CSPH, and the Rule of Five
Prevention of Decompensation
Nonselective Beta Blockers (NSBB)
Preventing
Preventing Decompensation ... Rule of Five Prevention ... Blockers (NSBB) Preventing ... #treatment #management ... #hepatology #gastroenterology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
management #algorithm #pharmacology ... #treatment #medications ... #table #pharmacotherapy ... decisionaid #cardiology #hematology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... DOACs thereby leading ... Chemotherapy #Oncology #Hematology ... #Interactions #Table ... #Pharmacology
Thrombotic Microangiopathy - TTP VS HUS

Big picture points : Often hard to differentiate the two entities,
distinction has HUGE treatment ... and first-line treatment ... Comparison #Diagnosis #Table ... #Hematology